Beaming in: new gene editing play raises $87M series A

Gene editing company Beam Therapeutics (Cambridge, Mass.) launched with an $87 million series A round co-led by F-Prime Capital Partners and Arch Venture Partners and IP licensed from

Read the full 284 word article

User Sign In